Autoantibodies Against DFS70/LEDGF Exclusion Markers for Systemic Autoimmune Rheumatic Diseases (SARD)

Seelig, Claudia A; Bauer, O.; Seelig, H. P.

doi:10.7754/clin.lab.2015.150905

Cited by 37 publications

(65 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Based on this trend, the complexity and heterogeneity of ANA screening populations change significantly from one clinical lab to the other. Systematic review for DFS70 autoantibody positivity has been performed by multiple groups [4, 6, 30]. The majority of clinical studies have used IIF-HEp2 for establishing a suspicion of DFS70 pattern and the rates of positivity for DFS70 autoantibodies in each group varied widely between studies [7, 9, 18, 21, 28, 31–44].…”

Section: Prevalence Of Dfs70 Autoantibodiesmentioning

confidence: 99%

“…The majority of clinical studies have used IIF-HEp2 for establishing a suspicion of DFS70 pattern and the rates of positivity for DFS70 autoantibodies in each group varied widely between studies [7, 9, 18, 21, 28, 31–44]. DFS70 antibodies have been reported in high titers from cohorts of healthy individuals, blood donors, patients being screened for ANA, patients with various autoimmune disorders and various non-autoimmune disorders including cancers [4, 6, 30]. These studies have shown that DFS70 autoantibodies lack distinct clinical association, with most disease groups, except for certain inflammatory conditions of eyes and skin [4, 6, 7, 18, 30, 44, 45].…”

Section: Prevalence Of Dfs70 Autoantibodiesmentioning

confidence: 99%

“…DFS70 antibodies have been reported in high titers from cohorts of healthy individuals, blood donors, patients being screened for ANA, patients with various autoimmune disorders and various non-autoimmune disorders including cancers [4, 6, 30]. These studies have shown that DFS70 autoantibodies lack distinct clinical association, with most disease groups, except for certain inflammatory conditions of eyes and skin [4, 6, 7, 18, 30, 44, 45]. The method of screening, selection, and composition of study cohorts may also influence the reported rates of DFS70 autoantibody positivity.…”

Section: Prevalence Of Dfs70 Autoantibodiesmentioning

confidence: 99%

“…3). Many reviews by experts in the field suggested the importance of confirming DFS70 suspicion using specific methods and evaluate its overall impact on ANA screening algorithm and associated costs [1, 4, 6, 30, 34, 39, 46–48]. As per certain studies, approximately a third of the positive ANA cases were positive for DFS70 pattern [9, 33].…”

Section: Prevalence Of Dfs70 Autoantibodiesmentioning

confidence: 99%

“…The ICAP committee described 28 distinct patterns on HEp-2 and assigned each pattern an AC (Anti-cell) number of 1–28 [3]. DFS70 AC-02 pattern has received the most scrutiny in the field in recent years due to its high rates of prevalence in healthy and ANA positive populations and negative association with SARD/AARD [4, 5]. …”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Analysis of DFS70 pattern and impact on ANA screening using a novel HEp-2 ELITE/DFS70 knockout substrate

Malyavantham

2017

Autoimmun Highlights

View full text Add to dashboard Cite

Indirect immunofluorescence (IIF) using human epithelial cell (HEp-2) substrate is a widely used and the recommended method for screening of antinuclear antibodies (ANA). Dense fine speckled (DFS70) pattern on HEp-2 has been widely reported in various healthy and disease groups. Interpretation of DFS70 pattern can be challenging on a conventional HEp-2 substrate due to its similarity to some of the disease associated patterns. The high prevalence of DFS70 autoantibodies in normal population, lack of association with a particular disease group and a general negative association with systemic and ANA associated autoimmune rheumatic diseases (SARD/AARD) necessitates the confirmation of DFS70 pattern. Results using available commercial assays for confirmation of DFS70 autoantibodies do not always agree with IIF screening results further complicating the lab work flow and ANA algorithms. In this review, we discuss the prevalence of DFS70 antibodies and factors affecting the performance of IIF and DFS70 specific confirmatory assays. Factors that contribute to disagreement between DFS70 suspicion by IIF and confirmatory assays will also be discussed. In addition, we also describe a novel IIF HEp-2 substrate, and its positive impact on DFS70 reporting and ANA screening-confirmation algorithm.

show abstract

Section: Prevalence Of Dfs70 Autoantibodiesmentioning

confidence: 99%

Section: Prevalence Of Dfs70 Autoantibodiesmentioning

confidence: 99%

Section: Prevalence Of Dfs70 Autoantibodiesmentioning

confidence: 99%

Section: Prevalence Of Dfs70 Autoantibodiesmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Analysis of DFS70 pattern and impact on ANA screening using a novel HEp-2 ELITE/DFS70 knockout substrate

Malyavantham

2017

Autoimmun Highlights

View full text Add to dashboard Cite

show abstract

Dense fine speckled immunofluorescence pattern in a Chinese population: Prevalence and clinical association

Zhang

et al. 2021

Clinical Laboratory Analysis

View full text Add to dashboard Cite

Objective To provide information on the prevalence and possible clinical association in a Chinese population for medical practice of the dense fine speckled pattern (DFS pattern). Methods A retrospective study was conducted with patients who had the DFS pattern from June 2018 to December 2019 in West China Hospital. Results A total of 469 patients (1.27% of patients with positive anti‐nuclear antibody indirect immunofluorescence (ANA IIF) test results) revealed the DFS pattern, of which 92.96% had isolated DFS pattern and 23.67% had titers above/equal to 1:320. The average age of patients with the DFS pattern was 43.45 years, and females accounted for 76.97% of them. Ten different kinds of diseases made up the vast majority of the disease spectrum, in which inflammatory or infectious diseases (46.11%), mental diseases (21.45%), and systemic autoimmune rheumatic diseases (SARDs) (18.23%) ranked in the top three. The most common SARDs were rheumatoid arthritis (RA), undifferentiated connective tissue disease (UCTD), and systemic lupus erythematosus (SLE). Forty‐six patients (10.55%) had positive or suspicious extractable nuclear antigen (ENA) antibodies test results and a higher risk of suffering from SARDs. Forty‐seven patients would be missed if the DFS pattern with negative ENA antibodies test result was considered as exclusion criterion of SARDs. Conclusions The DFS pattern is basically isolated and with low titer. It is unwise to exclude the diagnosis of SARDs only depending on the appearance of the DFS pattern. Autoimmune diseases‐related antibodies, clinical information of patients, and long‐term follow‐up are of great importance to avoid missed or delayed diagnosis of SARDs.

show abstract

Klinische Wertigkeit der Bestimmung von DFS70-Antikörpern für den Ausschluss von Kollagenosen

et al. 2019

View full text Add to dashboard Cite

Autoantibodies Against DFS70/LEDGF Exclusion Markers for Systemic Autoimmune Rheumatic Diseases (SARD)

Cited by 37 publications

References 0 publications

Analysis of DFS70 pattern and impact on ANA screening using a novel HEp-2 ELITE/DFS70 knockout substrate

Analysis of DFS70 pattern and impact on ANA screening using a novel HEp-2 ELITE/DFS70 knockout substrate

Dense fine speckled immunofluorescence pattern in a Chinese population: Prevalence and clinical association

Klinische Wertigkeit der Bestimmung von DFS70-Antikörpern für den Ausschluss von Kollagenosen

Contact Info

Product

Resources

About